主旨
癌症研究
糖基化
PDGFRA公司
间充质干细胞
间质细胞
舒尼替尼
下调和上调
胃肠道
生物
间质瘤
生物标志物
岩藻糖基化
酪氨酸激酶
细胞培养
原癌基因蛋白质c-kit
体外
靶向治疗
受体酪氨酸激酶
激酶
S100A9型
甲磺酸伊马替尼
细胞
癌症
化学
基因敲除
糖蛋白
肿瘤进展
细胞生长
酪氨酸激酶抑制剂
N-连接糖基化
苦马豆素
医学
作者
Jiahao Liu,Sihan Wu,Yunfei Wang,Ge Zhang,Jiehan Li,Zhen Wang,Yuhan Yin,Hao Liu,Sanfei Peng,Yang Fu
标识
DOI:10.1093/pcmedi/pbag016
摘要
Abstract Background Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is mainly driven by activating KIT or PDGFRA mutations. Although tyrosine kinase inhibitors (TKIs) improve outcomes, primary and acquired resistance remain major challenges, especially in high-risk and wild-type GIST. Protein O-linked N-acetylgalactosamine (O-GalNAc) glycosylation regulates protein stability and signaling, but its role in GIST remains unclear. Methods Bulk RNA-seq, proteomic, and single-cell RNA-seq data were integrated to identify O-glycosylation-related programs and key glycosyltransferases in GIST. Functional assays in GIST-T1 and GIST-882 cells, together with xenograft models, were performed to assess the effects of GalNAc-transferase 7 (GALNT7). GALNT7–KIT interaction, KIT O-GalNAcylation, and protein stability were examined by co-immunoprecipitation, VVA lectin blotting, confocal microscopy, and cycloheximide chase assays. Benzyl-α-GalNAc was evaluated as an O-glycosylation-targeting strategy in vitro and in vivo. Results O-glycosylation signatures were enriched in high-risk GIST and correlated with pathological risk. High O-glycosylation scores co-segregated with elevated copy-number variation in a fibroblast-like malignant cell population. GALNT7 was identified as a hub gene, upregulated in GIST, and associated with poor progression-free survival. GALNT7 promoted GIST cell growth, migration, and xenograft formation. Mechanistically, GALNT7 interacted with KIT, catalyzed its Tn-antigen O-GalNAcylation, increased KIT protein stability, and sustained PI3K/AKT and MAPK/ERK1/2 signaling. Benzyl-α-GalNAc reduced KIT O-GalNAcylation and stability, attenuated GALNT7-driven phenotypes, and inhibited xenograft growth. Conclusions GALNT7-mediated O-GalNAc glycosylation stabilizes KIT and drives GIST progression. GALNT7 may serve as a prognostic biomarker and therapeutic target in GIST.
科研通智能强力驱动
Strongly Powered by AbleSci AI